Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3

Author:

Jaiyesimi Ishmael A.1,Leighl Natasha B.2ORCID,Ismaila Nofisat3ORCID,Alluri Krishna4ORCID,Florez Narjust5ORCID,Gadgeel Shirish6ORCID,Masters Gregory7ORCID,Schenk Erin L.8ORCID,Schneider Bryan J.9,Sequist Lecia10ORCID,Singh Navneet11ORCID,Bazhenova Lyudmila12ORCID,Blanchard Elizabeth13,Freeman-Daily Janet14ORCID,Furuya Naoki15ORCID,Halmos Balazs16ORCID,Azar Ibrahim Hanna17ORCID,Kuruvilla Sara18,Mullane Michael19,Naidoo Jarushka20ORCID,Reuss Joshua E.21ORCID,Spigel David R.22ORCID,Owen Dwight H.23ORCID,Patel Jyoti D.24ORCID

Affiliation:

1. Corewell Health William Beaumont University Hospital, Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, MI

2. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

3. American Society of Clinical Oncology (ASCO), Alexandria, VA

4. St Luke's Mountain States Tumor Institute, Boise, ID

5. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

6. Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI

7. Helen F. Graham Cancer Center and Research Institute, Newark, DE

8. University of Colorado Anschutz Medical Center, Aurora, CO

9. University of Michigan Health System, Ann Arbor, MI

10. Massachusetts General Hospital, Boston, MA

11. Postgraduate Institute of Medical Education and Research, Chandigarh, India

12. University of California San Diego Moores Cancer Center, San Diego, CA

13. Southcoast Centers for Cancer Care, New Bedford, MA

14. The ROS1ders, Seattle, WA

15. St Marianna University School of Medicine, Kawasaki, Japan

16. Montefiore Einstein Center for Cancer Care, Bronx, NY

17. IHA Hematology Oncology Consultants, Ypsilanti, MI

18. London Health Sciences Centre, London, ON, Canada

19. Aurora Cancer Care, Mount Pleasant, WI

20. Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

21. Georgetown University, Washington, DC

22. Sarah Cannon Research Institute, Nashville, TN

23. Ohio State University, Columbus, OH

24. Northwestern University, Chicago, IL

Abstract

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Eight new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients based on targetable driver alterations. Additional information is available at www.asco.org/living-guidelines .

Publisher

American Society of Clinical Oncology (ASCO)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3